Separate science from politics: save the UK’s science sector

LifeArc's Chief Scientific Officer calls for UK science to continue to be a contributor to the Horizon Europe programme.

Promising new antibody treatment for osteoporosis and multiple sclerosis

The new antibody offers hope of an effective new treatment option for millions of people.

Her Majesty Queen Elizabeth II

We at LifeArc are deeply saddened by the passing of our monarch, Her Majesty Queen Elizabeth II.…

LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science

LifeArc helps create new MRC spin-out company

Our technology transfer team played a crucial role in the formation of Constructive Bio, a new Medical…

Driving translational research into childhood rare diseases

Four grants awarded to projects that aim to translate research discoveries into benefits for children affected by rare diseases

New £4.25 million grant kick starts UK-wide collaborative research effort to end motor neuron disease

Collaboration will work together to find solutions to MND within years, not decades

New £30 million translational partnership will accelerate development of new treatments for people with dementia

Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.

Promising new asthma medicine ready to enter early clinical trials

LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe asthma